Lilly stock rises after drugmaker reports higher sales
Investors responded favorably Thursday to Eli Lilly and Co.’s surprisingly strong second-quarter revenue, even though its profit fell due to rapid spending on marketing and research.
Investors responded favorably Thursday to Eli Lilly and Co.’s surprisingly strong second-quarter revenue, even though its profit fell due to rapid spending on marketing and research.
Pfizer Inc., the world’s biggest drugmaker, said it isn’t interested in breaking up its animal health unit after Indianapolis-based Eli Lilly and Co. expressed interest in buying some of its products.
Second-quarter profit fell at Eli Lilly and Co., but the Indianapolis drugmaker beat the estimates of Wall Street analysts by a penny per share and raised its full-year profit forecast by as much as 10 cents per share.
It was the biggest turnout for an education event I have ever seen in Indiana.
The Indianapolis Convention & Visitors Association plans to attract more life sciences conferences.
Eli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug semagacestat didn’t improve after dosing was halted.
Dapagliflozin would be the first in a new class of diabetes treatments called SGLT2-inhibitors that work by letting patients excrete excess blood sugar in their urine. Indianapolis-based Eli Lilly and Co. is among several companies pursuing similar drugs.
Noblesville-based Riverview Hospital is set to scoop up nine physicians from Indianapolis-based physician group American Health Network. The nine doctors include seven in Noblesville and two in Sheridan. American Health Network also will transfer its lease on a medical office and imaging center on River Avenue in Noblesville. The deals are set to close on July 29. Riverview officials declined to comment. Indianapolis-area hospitals have acquired a wave of physicians in the past three years. The deals are driven in part by flat or in some cases declining reimbursement rates for physicians, looming new expenses for electronic medical record systems and new provisions in the 2010 health reform law that encourage doctors and hospitals to work more closely.
Joblessness and economic jitters continue to weigh on the orthopedic industry, according to the latest financial report from Warsaw-based Biomet Inc. The company’s U.S. sales declined 3 percent to $412 million in its fourth quarter ended May 31, compared with the same quarter a year ago. Worldwide sales rose 2 percent to $715.2 million, but that was only because of currency fluctuations since this time last year. “During our fiscal fourth quarter, our sales results continued to be challenged by industry volume and price pressures that affected our sales throughout fiscal 2011,” Biomet CEO Jeffrey Binder said in a prepared statement. For the year, Biomet’s sales rose just 1 percent to $2.7 billion. The lack of growth forced Biomet to lower its valuation of many of its assets, leading to various accounting charges that produced yearly and fourth-quarter losses. Biomet’s results are watched as a key bellwether for the rest of the orthopedic industry, including Warsaw-based Zimmer Holdings Inc., which will report financial results later this month.
Wishard Health Services announced $3.2 million in fundraising for its new hospital last week, part of a campaign that has already exceeded its $50 million goal. An employee-giving campaign for the new Wishard medical center brought in about $2.2 million, making the campaign one of the largest of its kind for a public hospital, according to Wishard officials. More than 1,000 employees gave $1.1 million to the campaign, and an anonymous donor provided a dollar-for-dollar match. Wishard officials said employee giving rose 40 percent after the June 22 announcement of a $40 million gift from Indianapolis developer Sidney Eskenazi and his wife, Lois. The hospital complex that is to open in 2014 will be named the Sidney and Lois Eskenazi Hospital. Also, Wishard will rename itself Eskenazi Health in 2014. Wishard also received $1 million toward the new hospital from Eli Lilly and Co. Foundation. Lilly's name will grace the lobby of the new hospital
An employee-giving campaign for the new Wishard medical center brought in about $2.2 million, making the campaign one of the largest of its kind for a public hospital, according to Wishard Health Services officials.
Purdue University has named P. Christopher Earley, dean at the University of Connecticut School of Business, to take over as dean of Purdue’s Krannert School of Management.
Eli Lilly & Co. CEO John C. Lechleiter said Germany’s overhaul of drug pricing lacked transparency and the new policy creates “uncertainty” for the company’s business planning.
Why do drugmakers still pursue so many me-too drugs? Because, if marketed well, they can be extremely lucrative. Just ask Eli Lilly and Co. about its drug Cialis.
Janssen Pharmaceutica said Thursday it has completed the sale of its animal health business to Eli Lilly and Co. Inc.
Purdue just added a large tenant to the Indianapolis research park, bringing the total to 14.
The High Court in London on Tuesday denied Lilly’s request for a judgment without trial against Neopharma Ltd., the closely held company that has European marketing rights for the generic version of the drug known chemically as olanzapine.
To understand the depths of the pharmaceutical industry’s recent struggles, consider this: The industry has been spending $57 billion more per year on research and development than the value of the products it has been launching. That’s a problem.
Eli Lilly and Co., once the undisputed leader in the U.S. diabetes market, wants to regain its dominance by launching as many as four new diabetes drugs in the next five years, Lilly executives said during an investor meeting June 30. Lilly has lost large chunks of market share in the past decade to Denmark-based Novo Nordisk A/S and France-based Sanofi-Aventis SA. But this year, Lilly, through a partnership with Germany-based launched Boehringer Ingelheim GmbH, launched Tradjenta, a once-daily tablet that will compete with Merck & Co. Inc.’s successful Januvia but could involve fewer complications for patients with liver or kidney problems. As early as next year, Lilly could get the green light on Bydureon, a long-delayed once-weekly version of its Byetta treatment, developed with Amylin Pharmaceuticals Inc. Lilly could seek regulatory approval in 2013 for dulaglutide, a once-a-month drug similar to Bydureon. An oral drug called empagliflozin, also gained through the agreement with Boehringer Ingelheim, could launch in 2014. "Diabetes is one of the great opportunities for Lilly moving forward," Jan Lundberg, president of Lilly Research Laboratories, said in an interview with Reuters.
As part of its agreement to add Westview Hospital to its system, Community Health Network will assume $10 million in debt, spend $7.5 million on upgrades, and help open an outpatient center in Speedway, the two hospitals announced June 28. They will also look for more locations in western Indianapolis to add outpatient centers. Community and Westview first announced in November they were in talks to form a “strategic alliance.” On June 24, Westview’s board approved the merger. Westview needed to get bigger, CEO Jon Anderson said, because the 2010 health care reform law and other national trends are pushing hospitals to have some of their revenue hinge on whether they keep a specific population of patients healthy. Westview had annual revenue of $106 million in 2009, the most recent figure available. Community is more than 10 times as large, with annual revenue of $1.3 billion. From Community’s perspective, Westview helps it expand into the western portion of Indianapolis for the first time. In addition to Anderson, Community has hospitals in the southern, eastern and northeastern suburbs of Indianapolis. Community wants to make sure it has facilities accessible on all sides of the city in order to be attractive to employers who want to contract with a hospital system—either directly or through an insurer—that will take responsibility for keeping the employees healthy.
Indiana University Health is losing its chief financial officer, who has overseen the hospital system’s bulging balance sheet since 1999. Marvin Pember, 58, is taking a new job near Philadelphia as president of the acute care division of Universal Health Services Inc., a publicly traded company with 22 acute hospitals and numerous behavioral health centers spread from coast to coast. Pember’s last day at IU Health will be July 29. IU Health, an 18-hospital system based in Indianapolis, will begin a national search for his replacement immediately. Pember joined IU Health, then known as Clarian Health, when it had just three hospitals—Methodist, Indiana University Hospital and Riley Hospital for Children—all in downtown Indianapolis. Today, its hospitals stretch from LaPorte and Goshen in northern Indiana to Paoli and Bedford in the south. IU Health also has three more facilities set to join its fold by year’s end.
Eli Lilly and Co., the Indianapolis-based drugmaker whose best-selling schizophrenia medicine Zyprexa survived a patent challenge in Britain two years ago, has asked a United Kingdom judge to reject a parallel lawsuit by a generic drug company.
Eli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the world’s most successful biotech medicines, which are about to see their patents expire.
The Indiana State Museum begins a new fiscal year Friday with a different governance structure and a $1.1 million surplus.